The vaccine doses of Covaxin and Covishield manufactured by Hyderabad's Bharat Biotech and Pune's Serum Institute of India accordingly were unable to meet the demand to vaccinate the vast population of the country.
As a shot in the arm, one more vaccine is expected to be made available in India from earlier this year. The United States vaccine will be launched in India by the SII. The vaccine named Novavax has an efficacy of over 90 percent, as per the manufacturers.
The other day, the Novavax, Inc biotechnology company said that the vaccine dose has reported the effectiveness of 90.4 percent in preventing mild and moderate Covid in the clinical trials conducted in the United States and Mexico.
Novavax reported high efficacy percent after Moderna Inc. and Pfizer Inc's vaccine doses. The two doses reported an efficacy rate of 94 percent and 95 percent respectively.
To spread its wings, Novavax has partnered with other pharma companies in different countries. As part of this, the company joined hands with the Serum Institute of India to supply the vaccine in India.
The Pune-based Pharma giant is expected to apply for the emergency authorisation after more details of the clinical trials of the vaccine arrive. It is said that Covavax would manufacture 20 crore vaccines by earlier this year. This would be a game-changer concerned with the vaccination drive.